Literature DB >> 27121156

Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Kazuhiro Kitajima1, Hiroshi Doi2, Tomonori Kanda3, Tomohiko Yamane4, Tetsuya Tsujikawa5, Hayato Kaida6, Yukihisa Tamaki7, Kozo Kuribayashi8.   

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) using 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluation in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool for managing patients with lung cancer. We discuss different patient management stages, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.

Entities:  

Keywords:  Fluorodeoxyglucose (FDG); Lung cancer; Positron emission tomography/computed tomography (PET/CT); Staging; Treatment response assessment

Mesh：

Substances：

Year:  2016        PMID： 27121156     DOI： 10.1007/s11604-016-0546-2

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN： 1867-1071            Impact factor:   2.374


  93 in total

1.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

2.  Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.

Authors:  Mariko Kishimoto; Shingo Iwano; Shinji Ito; Katsuhiko Kato; Rintaro Ito; Shinji Naganawa
Journal:  Lung Cancer       Date:  2014-09-16       Impact factor: 5.705

3.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

4.  A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

Authors:  M E R O'Brien; J S Myerson; J I G Coward; M Puglisi; L Trani; A Wotherspoon; B Sharma; G Cook; S Ashley; R Gunapala; S Chua; S Popat
Journal:  Eur J Cancer       Date:  2011-11-24       Impact factor: 9.162

Review 5.  Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non--small-cell lung cancer.

Authors:  Evangelia Skoura; Ioannis E Datseris; Ioannis Platis; Georgios Oikonomopoulos; Konstantinos N Syrigos
Journal:  Clin Lung Cancer       Date:  2011-12-01       Impact factor: 4.785

Review 6.  Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.

Authors:  Ming-Che Chang; Jin-Hua Chen; Ji-An Liang; Cheng-Chieh Lin; Kuang-Tao Yang; Kai-Yuan Cheng; Jun-Jun Yeh; Chia-Hung Kao
Journal:  Acad Radiol       Date:  2011-12-14       Impact factor: 3.173

7.  Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Authors:  Hyung-Jun Im; Kyoungjune Pak; Gi Jeong Cheon; Keon Wook Kang; Seong-Jang Kim; In-Joo Kim; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-06       Impact factor: 9.236

8.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 9.  Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.

Authors:  Feifei Na; Jingwen Wang; Cong Li; Lei Deng; Jianxin Xue; You Lu
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

10.  Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

Authors:  D Ziai; T Wagner; A El Badaoui; A Hitzel; J B Woillard; B Melloni; J Monteil
Journal:  Cancer Imaging       Date:  2013-03-05       Impact factor: 3.909
View more
  4 in total

1.  Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy.

Authors:  Anastasia Oikonomou; Farzad Khalvati; Pascal N Tyrrell; Masoom A Haider; Usman Tarique; Laura Jimenez-Juan; Michael C Tjong; Ian Poon; Armin Eilaghi; Lisa Ehrlich; Patrick Cheung
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

2.  Lung cancer imaging methods in China from 2005 to 2014: A national, multicenter study.

Authors:  Dong-Hui Hou; Shi-Jun Zhao; Ju-Fang Shi; Le Wang; De-Bin Wang; Yun-Chao Huang; Xian-Zhen Liao; Xiao-Jing Xing; Ling-Bin Du; Li Yang; Yu-Qin Liu; Yong-Zhen Zhang; Dong-Hua Wei; Yun-Yong Liu; Kai Zhang; Ni Li; Wan-Qing Chen; You-Lin Qiao; Jie He; Min Dai; Ning Wu
Journal:  Thorac Cancer       Date:  2019-02-08       Impact factor: 3.500

3.  Performance of Ultrasound-Guided Core Biopsy Driven by FDG-avid Supraclavicular Lymph Nodes in Patients With Suspected Lung Cancer.

Authors:  Tongtong Wang; Junbao Liu; Ningning Lv; Shi Xuan; Lin Bai; Bin Ji; Shi Gao
Journal:  Front Med (Lausanne)       Date:  2022-01-20

Review 4.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.